For the millions who sleep strapped to a CPAP machine, a weekly injection now in trials may change the picture.
In two phase 3 trials, retatrutide significantly reduced sleep apnea severity and produced substantial weight loss in adults with overweight and obesity, with or without comorbid type 2 diabetes.
In two recent trials, Eli Lilly's retatrutide significantly reduced people's apnea episodes compared to a placebo.
Central sleep apnea (CSA) is fundamentally different from obstructive sleep apnea (OSA). The former is characterized by pauses in respiratory effort related to an unstable ventilatory system. This ...
New research suggests that a consumer smartwatch can help identify adults with moderate-to-severe obstructive sleep apnea, ...
Eli Lilly's retatrutide, a potent obesity drug, significantly reduces obstructive sleep apnea symptoms, offering potential ...
Sleep apnea is a debilitating disease that many sufferers don’t even realize they have. Those afflicted with the condition will regularly stop breathing during sleep as the muscles in their throat ...
Baller Alert on MSN
Sleep apnea could be going undetected in Black women, putting their heart health at risk
Black women may be living with a serious sleep disorder without realizing it, and new research suggests that the healthcare ...
Abu Dhabi (DoH) and Eight Sleep have signed a Memorandum of Understanding (MoU) to study the ways artificial intelligence (AI ...
Final 2025 CDC data show a record-low U.S. fertility rate of 53.2 and a 7% drop in teen births. What the numbers mean for maternity care access. Ric Flair Hospitalized Following Tampa Fall Hours After ...
Finding an effective, accessible solution for obstructive sleep apnea (OSA) can be life-changing. While CPAP machines are often prescribed, they're not always comfortable or convenient for everyone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results